NeuroPace Reports Record Q2 Revenue

NeuroPace (NPCE) reported record Q2 2025 revenue of $23.5 million, a 22% year-over-year increase, with a gross margin of 77.1%, and subsequently raised its full-year revenue outlook to $94-98 million. This strong financial performance was driven by robust RNS system sales and improved efficiency. Strategically, the company achieved significant progress in its NAUTILIST trial for generalized epilepsy, demonstrating over 80% median seizure reduction and securing FDA breakthrough device designation, positioning NPCE to access a new, large market. Furthermore, NeuroPace is leveraging its extensive 22 million-event data asset for AI development, enhancing its competitive moat and future product innovation.

Analysis

NeuroPace (NPCE) demonstrated strong operational execution and a clear growth trajectory in its Q2 2025 results. The company reported record revenue of $23.5 million, a 22% year-over-year increase, driven by robust sales of its core RNS system. Profitability metrics improved significantly, with gross margin expanding to 77.1% from 73.4% in the prior year, and the RNS system's specific gross margin exceeding 80%. This margin enhancement, coupled with operating expense growth of 13% being held well below revenue growth, indicates positive operating leverage. A key strategic catalyst is the promising progress of the NAUTILIST trial for idiopathic generalized epilepsy (IgE), which showed a median GTC seizure reduction exceeding 80% at 18 and 24 months and secured an FDA breakthrough device designation. This clinical success, with a PMA supplement submission planned for 2025, positions the company to access a large, underserved market. Furthermore, NeuroPace is fortifying its competitive moat by leveraging its proprietary dataset of over 22 million recorded brain events to develop AI-powered tools, creating a self-reinforcing data advantage that is difficult for competitors to replicate. Management's confidence is underscored by the decision to raise full-year 2025 revenue guidance to a range of $94 million to $98 million.

Key Decisions for Investors

• The combination of accelerating revenue growth, expanding gross margins, and positive operating leverage suggests a strong fundamental picture that warrants a bullish outlook on the company's core operations.
• Investors should closely monitor the 2025 PMA supplement submission for the RNS system in IgE, as FDA approval represents a significant near-term catalyst that could unlock a substantial new market and rerate the stock.
• Consider the long-term value of NeuroPace's unique and growing data asset, as its application in AI creates a durable competitive advantage that could drive sustained market leadership and future revenue streams.
• While phasing out the Dixie Medical product line is likely to improve margins, investors should track execution to ensure the core RNS business continues to deliver on its projected 20%+ growth to offset the divested revenue.